An external view of biopharma's R&D performance has resulted in unclear responses to a seemingly basic question: Has the industry improved or declined over the last decade? Market reports assert conflicting messages as definitions and measure of performance vary. This paper evaluates the heart of the industry's mission and the leading indicator of long-term success: R&D performance.
Alasdair Milton, PhD
Managing Director, Healthcare and Life Sciences Strategy, KPMG US
+1 617-988-5419
Related content
